How much does one injection of Donanemab cost?

Donanemab (Donanemab) is a new type of antibody drug mainly used to treat Alzheimer’s Disease (Alzheimer’s Disease). At present, the drug has been officially launched in China, but it has not yet been included in the national medical insurance system, which also results in domestic patients having to bear all costs when purchasing it. Since domestic prices have not yet been made public, patients need to go to the hospital or pharmacy to consult specific price information in order to make reasonable medication budgets and arrangements.

In overseas markets, the original drug specification of donenemab is usually 350mg/20mL and the price is relatively expensive. According to market conditions, the price of each box of the drug is approximately 20,000 yuan, but due to exchange rate fluctuations and drug pricing policies in different countries, the specific price may fluctuate to a certain extent. This price is a considerable financial burden for many patients, especially in the absence of medical insurance support, which further highlights the financial pressure on patients and families.

It is worth noting that there is currently no generic version of donenezumab on the market, which means that patients can only rely on the supply of the original drug, and it is difficult to reduce the price through generic drugs. This situation also reflects the difficulty of research and development and market monopoly status of donenezumab as an innovative drug. In the future, as technology advances and related patents expire, generic drugs may emerge, helping to alleviate the financial burden on patients.

In general, donelenumab has important clinical value in the treatment of Alzheimer's disease, but its high price and lack of coverage by medical insurance limit its popularity and application in China. When patients and their families choose to use this drug, in addition to considering the therapeutic effect, they also need to fully assess their financial affordability and actively pay attention to policy developments. They look forward to the introduction of more supportive policies in the future to help more patients obtain timely and effective treatment.

Reference materials:https://www.drugs.com/seladelpar.html